Paxmedica appoints david hough m.d. as chief medical officer

Announces additional management changes; independent directors now majority of board tarrytown, ny, aug. 16, 2023 (globe newswire) -- via newmediawire – paxmedica, inc. (nasdaq: pxmd), a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic drug therapies (apt) for the treatment of autism spectrum disorder (asd) and other serious conditions with intractable neurologic symptoms, today announced the return of david hough, m.d., as chief medical officer (cmo) of paxmedica, effective immediately.
PXMD Ratings Summary
PXMD Quant Ranking